Trial Profile
Vaccination Response Following Administration of Ixekizumab to Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary) ; DTaP vaccine; Pneumococcal vaccine
- Indications Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 07 Nov 2017 Primary endpoint (Percentage of Participants with an Immune Response to Tetanus and Pneumococcal Vaccinations) has been met, according to the results published in the BioDrugs
- 07 Nov 2017 Results published in the BioDrugs
- 17 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.